Exelixis
EXEL
#1695
Rank
C$13.88 B
Marketcap
$48.63
Share price
0.52%
Change (1 day)
69.29%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : C$3.17 Billion

According to Exelixis's latest financial reports the company has C$3.17 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$C$3.00 B-11.07%
2022-12-31$C$3.37 B19.86%
2021-12-31$C$2.81 B17.58%
2020-12-31$C$2.39 B8.81%
2019-12-31$C$2.20 B25.56%
2018-12-31$C$1.75 B389.51%
2017-12-31$C$0.35 B198.48%
2016-12-31$C$0.12 B-161.45%
2015-12-31$-C$0.2 Billion46.58%
2014-12-31$-C$0.14 Billion-288.99%
2013-12-31$C$70.51 M-76.08%
2012-12-31$C$0.29 B219.74%
2011-12-31$C$92.19 M-140.39%
2010-12-31$-C$0.23 Billion32.48%
2009-12-31$-C$0.18 Billion151.83%
2008-12-31$-C$68.41 Million-180.19%
2007-12-31$C$85.3 M-19.14%
2006-12-31$C$0.10 B58.15%
2005-12-31$C$66.7 M9.6%
2004-12-31$C$60.86 M-70.95%
2003-12-31$C$0.20 B-24.61%
2002-12-31$C$0.27 B-26.48%
2001-12-31$C$0.37 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
C$25.13 B 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$109.24 B 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
C$62.21 B 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
C$24.01 B 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
C$10.50 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
C$97.94 B 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
C$129.22 B 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$0.97 Million-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
C$40.27 M-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA